Cystic FibrosisNCT06222905
Analysis of Remote Monitoring/Virtual Clinic Data in Adult Patients With Cystic Fibrosis (Project Breathe)
An observational study of Cystic Fibrosis, run by Papworth Hospital NHS Foundation Trust at 2 sites in United Kingdom.
Trial summary
The goal of this observational study is to learn about the impact of home monitoring in adults with cystic fibrosis. The main questions it aims to answer are: how people with CF find using home monitoring equipment to see if by using home monitoring data acute respiratory exacerbations (chest infections) can be… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cystic Fibrosis
- What is being tested?
- non interventional
- How many people
- 475 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 20 Feb 2019to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with cystic fibrosis attending specialist cystic fibrosis centres
Who may be able to join
- Diagnosis of Cystic Fibrosis based on genetic testing and/or sweat chloride levels
- Age ≥ 18 years of age
- Able to provide written informed consent
- Patients who are known to be suitable for home monitoring and able to manage the process, those currently undertaking home monitoring / virtual clinics
Who cannot join
- Patients unable to provide written informed consent
- Patients unwilling to consent to their link anonymized data from home monitoring / virtual clinics being used for research
- Lung transplant recipients
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Royal Papworth Hospital
Cambridge, Cambridgeshire, CB2 0AA
Royal Papworth Hospital NHS Foundation Trust
Cambridge, Cambridgeshire, CB2 0BB
About this study
Official title: Analysis of Remote Monitoring / Virtual Clinic Data in Adult Patients With Cystic Fibrosis (CF)
The goal of this observational study is to learn about the impact of home monitoring in adults with cystic fibrosis. The main questions it aims to answer are:
- how people with CF find using home monitoring equipment
- to see if by using home monitoring data acute respiratory exacerbations (chest infections) can be detected earlier than standard care
Participants will be provided with a range of home monitoring equipment -
- hand held spirometer (lung function)
- weighing scales
- oximeter (blood oxygen levels)
- activity and heart rate monitor to measure health at home several times a week. This information links to an app on a smartphone which the participant and clinicians can see.
Read the detailed description
This is a multi-centre, observational, prospective cohort study. 610 adult patients with CF will be recruited from the following four CF centres within the United Kingdom
- Royal Papworth Hospital, Cambridge
- University Hospital Llandough, Penarth Wales
- Queen Elizabeth University Hospital, Glasgow, Scotland
- Western General Hospital, Edinburgh, Scotland.
The study is designed to run as a non-disruptive study with no impact on routine clinical practice. Each participant will be actively involved in home monitoring / virtual clinics. linked-anonymised data will be uploaded to a secure National Health Service The approved web-based site for analysis via Microsoft Azure which implements the transmission integrity and confidentiality control by ensuring that cryptography is implemented through a hybrid model.
Clinical metadata including physiology home monitor / virtual clinic data, sputum volume and colour recording will be analysed to establish whether there are predictive signals that could be used as an early alert to clinical deterioration.
Patient level costing will be compared across the cohort and with historical controls to estimate the cost saving or additional cost of home monitoring / virtual clinics.
The statistical data will be analysed by statisticians at the University of Cambridge, with analysis expertise input by Microsoft Research. The health economic data analysis will be carried out by statisticians at the University of Cambridge, with input from the CF Trust and Microsoft Research. A variety of different statistics packages will be utilised as appropriate.
The study specific questionnaire will be completed online by the patients through SurveyMonkey or in paper form if the patient prefers with the questionnaire taking approximately 15 minutes to complete.
All data will be link anonymised and the interviews that take place (at the lead site only) will generate identifiable data, however this will be restricted to the research team at Royal Papworth Hospital and anonymised prior to publication.
Study Duration The study will run for 12 years (with each participant enrolled for up to 5 years (60 months)). The anticipated start date would be 1st December 2018 with the expected end date of the 31 Dec 2030.
Study Activities and Data Collection
The duration of enrolment per participant will be up to 5 years (60 months). During the study period patient data will be collected on the following parameters:
- Physiology home monitor / virtual clinic data, sputum volume and colour recording metadata will be analysed to establish whether there are predictive signals that could be used as an early alert to clinical deterioration. The above parameters are routinely collected as part of normal clinical care, by using the 'Breathe Remote Monitor which is downloaded onto the patient's own smartphone Patients will need to have access to a Wi-Fi connection, but the app will not create any mobile data charges as long as connected to Wi-Fi. The patient can then sync the following devices:
- Fitbit - passive monitoring ii. Pulse oximeter - once daily iii. Spirometer - once daily iv. Weighing scales - once daily Anonymised data from the above devices will be uploaded and synced with the app. This will need to be done daily by the patient.
- Patient level costing data will be compared across the cohort and with historical controls to estimate the cost saving or additional cost of home monitoring / virtual clinics.
- Semi- structured interviews (at the lead site only) and questionnaires completed through SurveyMonkey or paper (patient can choose) to capture qualitative and quantitative impact of home monitoring / virtual clinics on CF patients. This aspect of the project is the only research procedures that the patients will be asked to undertake.
Patients will be asked to complete the following surveys at the timepoints listed below:
- Study specific survey completed through either SurveyMonkey or paper copy at 3, 12 and 24 months which will take approximately 15 minutes to complete, no further questionnaires will be required after the first 24 months only the continued collection of data as noted above.
- Conditions
- Cystic Fibrosis
- Being tested
- non interventional
- Medical subject headings
- Cystic Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
non interventionalOther
non interventional
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in the 12 domain Cystic Fibrosis Questionnaire Revised (CFQR) Score at 24 months
CFQR is a validated, self reported quality of life questionnaire. It has 12 domains such as physical and psychological health. It is a scaled score of 0 to 100. 0 being the worst and 100 the best.
Measured: 24 months
Secondary outcomes (1)
Change from baseline in lung function at 12 months
Lung function (FEV1 % predicted) is a validated measure of lung forced expiratory volume in 1 second.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2024
- Study start20 Feb 2019
- Primary completion25 Jan 2024
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cystic FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 475 participants (actual)
Sponsor and investigators
- Lead sponsor
- Papworth Hospital NHS Foundation Trust
- Sponsor type
- Other government
- Collaborators
- Innovate UK, Cystic Fibrosis Trust, US Cystic Fibrosis Foundation
- Responsible party
- Sponsor
- Investigators
- Andres Floto, Principal investigator, Royal Papworth Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06222905
- Sponsor's protocol ID
- P02445
- Status last verified
- May 2025
- First submitted
- 16 Jan 2024
- Last updated
- 31 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Remote Monitoring / Virtual Clinic Data in Adult Patients With Cystic Fibrosis (CF)
- ClinicalTrials.gov ID
- NCT06222905
- Acronym / sponsor ID
- P02445
- Conditions
- Cystic Fibrosis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 475 participants (actual)
- Lead sponsor
- Papworth Hospital NHS Foundation TrustOther government
- Collaborators
- Innovate UK, Cystic Fibrosis Trust, US Cystic Fibrosis Foundation
- Study start
- 20 Feb 2019 (actual)
- Primary completion
- 25 Jan 2024 (actual)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 25 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the impact of home monitoring in adults with cystic fibrosis. The main questions it aims to answer are:
- how people with CF find using home monitoring equipment
- to see if by using home monitoring data acute respiratory exacerbations (chest infections) can be detected earlier than standard care
Participants will be provided with a range of home monitoring equipment -
- hand held spirometer (lung function)
- weighing scales
- oximeter (blood oxygen levels)
- activity and heart rate monitor to measure health at home several times a week. This information links to an app on a smartphone which the participant and clinicians can see.
Detailed description
This is a multi-centre, observational, prospective cohort study. 610 adult patients with CF will be recruited from the following four CF centres within the United Kingdom
- Royal Papworth Hospital, Cambridge
- University Hospital Llandough, Penarth Wales
- Queen Elizabeth University Hospital, Glasgow, Scotland
- Western General Hospital, Edinburgh, Scotland.
The study is designed to run as a non-disruptive study with no impact on routine clinical practice. Each participant will be actively involved in home monitoring / virtual clinics. linked-anonymised data will be uploaded to a secure National Health Service The approved web-based site for analysis via Microsoft Azure which implements the transmission integrity and confidentiality control by ensuring that cryptography is implemented through a hybrid model.
Clinical metadata including physiology home monitor / virtual clinic data, sputum volume and colour recording will be analysed to establish whether there are predictive signals that could be used as an early alert to clinical deterioration.
Patient level costing will be compared across the cohort and with historical controls to estimate the cost saving or additional cost of home monitoring / virtual clinics.
The statistical data will be analysed by statisticians at the University of Cambridge, with analysis expertise input by Microsoft Research. The health economic data analysis will be carried out by statisticians at the University of Cambridge, with input from the CF Trust and Microsoft Research. A variety of different statistics packages will be utilised as appropriate.
The study specific questionnaire will be completed online by the patients through SurveyMonkey or in paper form if the patient prefers with the questionnaire taking approximately 15 minutes to complete.
All data will be link anonymised and the interviews that take place (at the lead site only) will generate identifiable data, however this will be restricted to the research team at Royal Papworth Hospital and anonymised prior to publication.
Study Duration The study will run for 12 years (with each participant enrolled for up to 5 years (60 months)). The anticipated start date would be 1st December 2018 with the expected end date of the 31 Dec 2030.
Study Activities and Data Collection
The duration of enrolment per participant will be up to 5 years (60 months). During the study period patient data will be collected on the following parameters:
- Physiology home monitor / virtual clinic data, sputum volume and colour recording metadata will be analysed to establish whether there are predictive signals that could be used as an early alert to clinical deterioration. The above parameters are routinely collected as part of normal clinical care, by using the 'Breathe Remote Monitor which is downloaded onto the patient's own smartphone Patients will need to have access to a Wi-Fi connection, but the app will not create any mobile data charges as long as connected to Wi-Fi. The patient can then sync the following devices:
- Fitbit - passive monitoring ii. Pulse oximeter - once daily iii. Spirometer - once daily iv. Weighing scales - once daily Anonymised data from the above devices will be uploaded and synced with the app. This will need to be done daily by the patient.
- Patient level costing data will be compared across the cohort and with historical controls to estimate the cost saving or additional cost of home monitoring / virtual clinics.
- Semi- structured interviews (at the lead site only) and questionnaires completed through SurveyMonkey or paper (patient can choose) to capture qualitative and quantitative impact of home monitoring / virtual clinics on CF patients. This aspect of the project is the only research procedures that the patients will be asked to undertake.
Patients will be asked to complete the following surveys at the timepoints listed below:
- Study specific survey completed through either SurveyMonkey or paper copy at 3, 12 and 24 months which will take approximately 15 minutes to complete, no further questionnaires will be required after the first 24 months only the continued collection of data as noted above.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with cystic fibrosis attending specialist cystic fibrosis centres
Key inclusion criteria (4 listed)
- Diagnosis of Cystic Fibrosis based on genetic testing and/or sweat chloride levels
- Age ≥ 18 years of age
- Able to provide written informed consent
- Patients who are known to be suitable for home monitoring and able to manage the process, those currently undertaking home monitoring / virtual clinics
Key exclusion criteria (3 listed)
- Patients unable to provide written informed consent
- Patients unwilling to consent to their link anonymized data from home monitoring / virtual clinics being used for research
- Lung transplant recipients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| non interventionalnon interventional | Other | – |
Primary outcome
Change from baseline in the 12 domain Cystic Fibrosis Questionnaire Revised (CFQR) Score at 24 months
Time frame: 24 months
CFQR is a validated, self reported quality of life questionnaire. It has 12 domains such as physical and psychological health. It is a scaled score of 0 to 100. 0 being the worst and 100 the best.
1 secondary outcome
Change from baseline in lung function at 12 months
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Cystic Fibrosis
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
Cystic Fibrosis - Complete
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andres Floto principal investigator
Royal Papworth Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cystic Fibrosis, run by Papworth Hospital NHS Foundation Trust at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in the 12 domain Cystic Fibrosis Questionnaire Revised (CFQR) Score at 24 months (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2025.